Charles Schwab’s CalciMedica CALC Stock Holding History

Charles Schwab’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,674	Closed	-$128K	–	3509
2021 Q2	$128K	Sell	1,674 -924	-36%	-$60.6K	﹤0.01%	3284
2021 Q1	$202K	Sell	2,598 -197	-7%	-$59K	﹤0.01%	3319
2020 Q4	$1.14M	Buy	+2,795	New	+$825K	﹤0.01%	2732

Other funds holding CALC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's CALC Position: Q3 2021 in Review

Charles Schwab sold out of CalciMedica (CALC) in Q3 2021, closing a stake of 1,674 shares — an estimated $128K sold.

Charles Schwab first reported a position in CALC in Q4 2020 and held it in 3 quarters. The position peaked at $1.14M in Q4 2020. 27 funds tracked by Wall St. Rank hold CALC as of Q3 2021.

Charles Schwab reported no remaining CalciMedica position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 1,674 CalciMedica shares in Q3 2021, an estimated $128K.
Charles Schwab first reported a position in CalciMedica in Q4 2020 and held it in 3 quarters.
Charles Schwab's CalciMedica position peaked at $1.14M in Q4 2020.
27 funds tracked by Wall St. Rank held CalciMedica as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.